Finance

Beta
Lists
SCNI:NASDAQ
Scinai Immunotherapeutics Ltd - ADR
$0.41
-6.08%
(-0.027) 1D
$0.44
+5.82% (+0.024)
After hours
Closed: Jun 5, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SCNI...
Open
$0.40
High
$0.42
Low
$0.37
Mkt. cap
1.63M
Avg. vol.
7.00M
Volume
1.27M
52-wk high
$3.47
52-wk low
$0.37
EPS
-$3.56
Beta
2.05
Shares outstanding
3.96M
No. of employees
45
Open
$0.40
High
$0.42
Low
$0.37
Mkt. cap
1.63M
Avg. vol.
7.00M
Volume
1.27M
52-wk high
$3.47
52-wk low
$0.37
EPS
-$3.56
Beta
2.05
Shares outstanding
3.96M
No. of employees
45
News stories
From sources across the web
Profile
BiondVax Pharmaceuticals Ltd. is an Israeli biopharmaceutical company focused on developing and manufacturing immunotherapeutic products, primarily for the treatment of infectious diseases and autoimmune diseases. In collaboration with the Max Planck Institute for Multidisciplinary Sciences and the University Medical Center Göttingen, both in Germany, BiondVax develops nanosized antibody therapies for diseases such as COVID-19, asthma and psoriasis. Wikipedia
About Scinai Immunotherapeutics Ltd - ADR
CEO-
Employees45
FoundedJan 1, 2003
Headquarters-
SectorBiotechnology
Websitescinai.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
386.50K
386.50K
269.00K
269.00K
Cost of goods sold
1.02M
1.02M
960.00K
960.00K
Cost of revenue
1.02M
1.02M
960.00K
960.00K
Research and development expenses
618.50K
618.50K
566.00K
566.00K
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
628.00K
628.00K
632.50K
632.50K
Operating expense
1.25M
1.25M
1.20M
1.20M
Total operating expenses
2.27M
2.27M
2.16M
2.16M
Operating income
-1.88M
-1.88M
-1.89M
-1.89M
Other non operating income
-
-
-3.50K
-3.50K
EBT including unusual items
-2.07M
-2.07M
-2.09M
-2.09M
EBT excluding unusual items
-2.07M
-2.07M
-2.09M
-2.09M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-2.07M
-2.07M
-2.09M
-2.09M
Net profit margin
-534.80%
-534.80%
-775.65%
-775.65%
Earnings per share
-
-
-
-
Interest and investment income
-
-
16.00K
16.00K
Interest expense
-185.50K
-185.50K
-
-
Net interest expenses
-185.50K
-185.50K
16.00K
16.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-1.53M
-1.53M
-1.53M
-1.53M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer